In overweight or obese patients, the risk of aggressive PCa is related to systemic effects such as dyslipidemia, increased serum concentrations of inflammatory factors like IL-6, IL-8, vascular endothelium growth factor, and leptin, as well as the deregulation of the insulin/insulin-growth factor 1 axis. The gene discussed is INS; the disease is metabolic syndrome.